Alto Neuroscience (Alto Neuroscience) Debt-to-Asset : 0.05 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Debt-to-Asset?

Alto Neuroscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.20 Mil. Alto Neuroscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $8.81 Mil. Alto Neuroscience's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $209.92 Mil. Alto Neuroscience's debt to asset for the quarter that ended in Mar. 2024 was 0.05.

Alto Neuroscience Debt-to-Asset Historical Data

The historical data trend for Alto Neuroscience's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Debt-to-Asset Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

0.19

0.12

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial			0.19	-	0.19	0.12	0.05

Competitive Comparison of Alto Neuroscience's Debt-to-Asset

For the Biotechnology subindustry, Alto Neuroscience's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's Debt-to-Asset falls into.

Alto Neuroscience Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alto Neuroscience's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.125	+	9.861)	/	86.628
	=	0.12

Alto Neuroscience's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.201	+	8.812)	/	209.922
	=	0.05

Alto Neuroscience (NYSE:ANRO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Alto Neuroscience Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024